AIMMAX THERAPEUTICS INC
Durham, NC · Founded 2016 · CIK 0001701803 · Biotech · Private
AMX-2005, a novel broad-spectrum antibiotic molecule with activity against MRSA and VRE
aimmaxrx.com →- Grants
- $6.8M
- 12 awards
- Sector median: 1
- Raised
- $200K
- 1 Form D · Apr 2017
- 114 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 9
- 0 granted · 9 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $200,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Optimization and Characterization of Novel Antifungal Peptides | $612,894 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Optimization and Characterization of Novel Antifungal Peptides | $306,486 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | $306,915 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization and Characterization of Novel Antifungal Peptides | $306,408 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Development of a Novel Injectable Antibiotic to Treat Serious Multidrug-resistant Gram-positive Infections | $306,954 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development of a Novel Injectable Antibiotic to Treat Serious Multidrug-resistant Gram-positive Infections | $306,954 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | $999,962 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | $999,962 | |
| Federal grant | Department of Health and Human Services · Phase II · A Single Dose Therapy to Treat Drug Resistant Gonorrhea | $306,497 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Novel Injectable Antibiotic to Treat Serious Multidrug-resistant Gram-positive Infections | $306,953 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | $999,991 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | $1,049,943 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1196 | VICOLINE MEDICAL, LLC | — | — |
| 1197 | Khartis Therapeutics | — | — |
| 1198 | TATEVA THERAPEUTICS INC. | — | — |
| 1199 | AIMMAX THERAPEUTICS INC | — | $200K |
| 1200 | DMC BIOTECHNOLOGIES, INC. | — | $47M |
| 1201 | Obatala Sciences, Inc. | — | $200K |
| 1202 | Oncorus, Inc. | — | $47M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Laurene WangDirector · Executive Officer
Patents
- Pristinamycin Ia And Flopristin Combinations In Treating Or Preventing Bacterial Infectionsapplication
- Peptides With Antimicrobial Activitiesapplication
- Streptogramin A Monotherapy For Treating Or Preventing Bacterial Infectionsapplication
- Corticosteroid Nanosuspensions And Uses For Treating Burn Injuries, Allergic Rhinitis, Meniere's Disease, Tenosynovitis And Arthritisapplication
- Use Of A Streptogramin A Monotherapy In Treating Or Preventing Bacterial Infectionsapplication
- Peptides With Antimicrobial Activitiesapplication
- Corticosteroid Nanosuspensions And Uses Thereofapplication
- Pristinamycin Ia And Flopristin Combinations In Treating Or Preventing Bacterial Infectionsapplication
- Corticosteroid Nanosuspensions And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.